Lambert JM, Chari RV. Ado-trastuzumab emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer. J Med Chem. 2014;57(16):6949–64.

Article  CAS  PubMed  Google Scholar 

Teicher BA, Morris J. Antibody-drug conjugate targets, drugs, and linkers. Curr Cancer Drug Targets. 2022;22(6):463–529.

Article  CAS  PubMed  Google Scholar 

Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Annu Rev Med. 2013;64:15–29.

Article  CAS  PubMed  Google Scholar 

Lambert JM. Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr Opin Pharmacol. 2005;5(5):543–9.

Article  CAS  PubMed  Google Scholar 

Carrasco-Triguero M, Dere RC, Milojic-Blair M, Saad OM, Nazzal D, Hong K, et al. Immunogenicity of antibody-drug conjugates: observations across 8 molecules in 11 clinical trials. Bioanalysis. 2019;11(17):1555–68.

Article  CAS  PubMed  Google Scholar 

Fiorotti CK. Immunogenicity considerations for antibody-drug conjugates: a focus on neutralizing antibody assays. Bioanalysis. 2018;10(2):65–70.

Article  CAS  PubMed  Google Scholar 

Xu W, Cummings J, Sank M, Juhel M, Li X, Gleason C, et al. Development and validation of a functional cell-based neutralizing antibody assay for ipilimumab. Bioanalysis. 2018;10(16):1273–87.

Article  CAS  PubMed  Google Scholar 

Papageorgiou SG, Thomopoulos TP, Liaskas A, Vassilakopoulos TP. Monoclonal antibodies in the treatment of diffuse large B-cell lymphoma: moving beyond rituximab. Cancers (Basel). 2022;14(8):1917.

Article  CAS  PubMed  Google Scholar 

Wang MMM, Barr PM, Barrientos J, de Vos S, Furman R, Patel K, Thompson PA, Choi M, Kallam A, Zhu Y, Chakraborty S, Marinello P, Spurgeon SE. P1231: zilovertamab vedotin (MK-2140) for the treatment of non-Hodgkin lymphoma: the phase 1 dose escalation and cohort expansion waveline-001 study of an anti-ROR1 antibody-drug conjugate. Hemasphere. 2022;23(6):1116–7.

Article  Google Scholar 

Aoyama M, Tada M, Yokoo H, Demizu Y, Ishii-Watabe A. Fcgamma receptor-dependent internalization and off-target cytotoxicity of antibody-drug conjugate aggregates. Pharm Res. 2022;39(1):89–103.

Article  CAS  PubMed  Google Scholar 

Mahalingaiah PK, Ciurlionis R, Durbin KR, Yeager RL, Philip BK, Bawa B, et al. Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates. Pharmacol Ther. 2019;200:110–25.

Article  CAS  PubMed  Google Scholar 

Nimmerjahn F, Ravetch JV. FcgammaRs in health and disease. Curr Top Microbiol Immunol. 2011;350:105–25.

CAS  PubMed  Google Scholar 

Lofgren JA, Wala I, Koren E, Swanson SJ, Jing S. Detection of neutralizing anti-therapeutic protein antibodies in serum or plasma samples containing high levels of the therapeutic protein. J Immunol Methods. 2006;308(1–2):101–8.

Article  CAS  PubMed  Google Scholar 

Milliken GAJ, D.E. Analysis of messy data, volume I: designed experiments.: Wadsworth, Inc., CA, USA; 1984. 211–45 p.

Shankar G, Devanarayan V, Amaravadi L, Barrett YC, Bowsher R, Finco-Kent D, et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal. 2008;48(5):1267–81.

Article  CAS  PubMed  Google Scholar 

FDA. Guide for Industry: Immunogenicity testing of therapeutic protein products — Developing and Validating Assays for Anti-drug Antibody Detection. 2019. https://www.fda.gov/media/119788/download

EMA. Scientific Guideline on Immunogenicity assessment of biotechnology-derived therapeutic protein. 2015. https://www.ema.europa.eu/en/immunogenicity-assessment-biotechnology-derived-therapeutic-proteins-scientific-guideline

Rasul E, Salamon D, Nagy N, Leveau B, Banati F, Szenthe K, et al. The MEC1 and MEC2 lines represent two CLL subclones in different stages of progression towards prolymphocytic leukemia. PLoS ONE. 2014;9(8):e106008.

Article  PubMed  PubMed Central  Google Scholar 

Fleck RA, Romero-Steiner S, Nahm MH. Use of HL-60 cell line to measure opsonic capacity of pneumococcal antibodies. Clin Diagn Lab Immunol. 2005;12(1):19–27.

CAS  PubMed  PubMed Central  Google Scholar 

Bournazos S, Wang TT, Ravetch JV. The role and function of Fc gamma receptors on myeloid cells. Microbiol Spectr. 2016;4(6):1–19.

Article  CAS  Google Scholar 

Temming AR, Bentlage AEH, de Taeye SW, Bosman GP, Lissenberg-Thunnissen SN, Derksen NIL, et al. Cross-reactivity of mouse IgG subclasses to human Fc gamma receptors: antibody deglycosylation only eliminates IgG2b binding. Mol Immunol. 2020;127:79–86.

Article  CAS  PubMed  Google Scholar 

Smith HW, Butterfield A, Sun D. Detection of antibodies against therapeutic proteins in the presence of residual therapeutic protein using a solid-phase extraction with acid dissociation (SPEAD) sample treatment prior to ELISA. Regul Toxicol Pharmacol. 2007;49(3):230–7.

Article  CAS  PubMed  Google Scholar 

Luong M, Wang Y, Donnelly BB, Lepsy C. Addressing domain specificity in the development of a cell-based binding assay for the detection of neutralizing antibodies against a CD47xPD-L1 bispecific antibody. AAPS J. 2023;25(6):91.

Article  CAS  PubMed  Google Scholar 

Singh AP, Sharma S, Shah DK. Quantitative characterization of in vitro bystander effect of antibody-drug conjugates. J Pharmacokinet Pharmacodyn. 2016;43(6):567–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gorovits B, Wakshull E, Pillutla R, Xu Y, Manning MS, Goyal J. Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics. J Immunol Methods. 2014;408:1–12.

Article  CAS  PubMed  Google Scholar 

Nguyen TD, Bordeau BM, Balthasar JP. Use of payload binding selectivity enhancers to improve therapeutic index of maytansinoid-antibody-drug conjugates. Mol Cancer Ther. 2023;22(11):1332–42.

Article  CAS  PubMed  Google Scholar 

Crabtree GR. Fc receptors of a human promyelocytic leukemic cell line: evidence for two types of receptors defined by binding of the staphylococcal protein A-IgG1 complex. J Immunol. 1980;125(1):448–53.

Article  CAS  PubMed  Google Scholar 

Ahmadi M, Bryson CJ, Cloake EA, Welch K, Filipe V, Romeijn S, et al. Small amounts of sub-visible aggregates enhance the immunogenic potential of monoclonal antibody therapeutics. Pharm Res. 2015;32(4):1383–94.

Article  CAS  PubMed  Google Scholar